Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

Development and validation of a questionnaire to measure asthma control

Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473

The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)

Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,212

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,873

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A., Cowley, H., Chung, K. F., Djukanović, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,810

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

Nair, P. K., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O’Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,346

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.bloodjournal79123101 · Cited by 972

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860

Eosinophil's Role Remains Uncertain as Anti–Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway

Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808

A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma

Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 590

Eosinophilia in transgenic mice expressing interleukin 5.

Dent, L. A., Strath, M., Mellor, A. L., & Sanderson, C. J. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.5.1425 · Cited by 579

Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma: A Pilot Study

KIPS, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A. A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F. M., & PAUWELS, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494

Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis

Stein, M., Collins, M. H., Villanueva, J. M., Kushner, J. P., Putnam, P. E., Buckmeier, B. K., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.007 · Cited by 459

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics

Menzies-Gow, A. N., Flood-Page, P. T., Sehmi, R., Burman, J. F., Hamid, Q. A., Robinson, D. S., Kay, A. B., & Denburg, J. A. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1382 · Cited by 276

Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis

Plötz, S. G., Simon, H., Darsow, U. G., Simon, D., Vassina, E. M., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 257

Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels

Stein, M., Villanueva, J. M., Buckmeier, B. K., Yamada, Y., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.033 · Cited by 143

Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia.

Wang, J., Palmer, K., Lötvall, J. O., Milan, S., Lei, X. F., Matthaei, K., Gauldie, J., Inman, M. D., Jordana, M., & Xing, Z. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2686 · Cited by 138

Proinflammatory Cytokines and Autoimmunity in Churg-Strauss Syndrome

Hellmich, B., Csernok, E., & Gross, W. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1361.053 · Cited by 136

Sustained response to mepolizumab in refractory Churg-Strauss syndrome

Kahn, J., Grandpeix‐Guyodo, C., Marroun, I., Catherinot, É., Mellot, F., Roufosse, F. E., & Blétry, O. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.10.014 · Cited by 117

Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies

Martin, R. M., Wilton, L., & Mann, R. D. (1999) · Pharmacoepidemiology and Drug Safety · doi:10.1002/(sici)1099-1557(199905/06)8:3 · Cited by 105

Remnants of suicidal cells fostering systemic autoaggression: Apoptosis in the origin and maintenance of autoimmunity

Rovere, P. Q., Sabbadini, M. G., Fazzini, F., Bondanza, A., Zimmermann, V. S., Rugarli, C., & Manfredi, A. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8 · Cited by 85

Pharmacokinetics and Pharmacodynamics of SB-240563, a Humanized Monoclonal Antibody Directed to Human Interleukin-5, in Monkeys

Zia‐Amirhosseini, P., Minthorn, E. A., Benincosa, L. J., Hart, T. K., Hottenstein, C. S., Tobia, L. A. P., & Davis, C. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35210-3 · Cited by 77

Anti-Interleukin-5 Monoclonal Antibodies

Leckie, M. J. (2003) · American Journal of Respiratory Medicine · doi:10.1007/bf03256653 · Cited by 74

Eosinophil Active Cytokines and Surface Analysis of Eosinophils in Churg-Strauss Syndrome

Tsukadaira, A., Okubo, Y., Kitano, K., Horie, S., Momose, T., Takashi, S., Suzuki, J.-I., Isobe, M., & Sekiguchi, M. (1999) · Allergy and Asthma Proceedings · doi:10.2500/108854199778681486 · Cited by 74

Involvement of Soluble CD95 in Churg-Strauss Syndrome

Müschen, M., Warskulat, U., Perniok, A., Even, J., Moers, C., Kismet, B., Temizkan, N., Simon, D., Schneider, M. B., & Häussinger, D. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65191-7 · Cited by 67

Asthma drug use and the development of Churg–Strauss syndrome (CSS)

Harrold, L. R., Patterson, M. K., Andrade, S. E., Dube, T., Go, A. S., Buist, A. S., Chan, K. A., Weller, P. F., Wechsler, M. E., Yood, R. A., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1353 · Cited by 60

Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome

Schnabel, A., Csernok, E., Braun, J., & Gross, W. L. (1999) · Thorax · doi:10.1136/thx.54.9.771 · Cited by 52

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Wechsler, M. E., Akuthota, P., Jayne, D. G., Khoury, P., Klion, A. D., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,091

International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis

Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

Assa’ad, A., Gupta, S. K., Collins, M. H., Thomson, M. A., Heath, A. T., Smith, D. A., Perschy, T. L., Jurgensen, C. H., Ortega, H. G., & Aceves, S. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.044 · Cited by 438

Targeting cytokines to treat asthma and chronic obstructive pulmonary disease

Barnes, P. J. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 432

Mepolizumab as a Steroid-Sparing Treatment in the Churg Strauss Syndrome.

Sh, K., Israel, E., Oren, E., & Wechsler, M. E. (2009) · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5468 · Cited by 2

Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.

Bjerrum, A., Schmid, J., & Skjold, T. (2018) · doi:10.1183/13993003.congress-2018.pa601 · Cited by 2

Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis.

Cassone, G., Sebastiani, M., Cataleta, P., Olivi, E., Gurioli, C., Cerri, S., Beghé, B., Giuggioli, D., & Manfredi, A. (2025) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v42i1.16311 · Cited by 1

Rationale and design of a placebo-controlled trial to evaluate the steroid-sparing effects of anti-IL5 monoclonal antibody (mepolizumab): Focus on cutaneous outcomes in patients with hypereosinophilic syndrome (HES)

(2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.347

Late-breaking abstract: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study

Bel, E. H., Wenzel, S., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S., Ortega, H., & Pavord, I. D. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.2907 · Cited by 10